Krystal Biotech Inc reports results for the quarter ended June 30 - Earnings Summary

Krystal Biotech

03/08/2026 14:31

Krystal Biotech Inc KRYS.OQ reported quarterly adjusted earnings of $1.79​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $1.29.  The mean expectation of ten analysts for the quarter was for earnings of $1.66 per share. Wall Street expected results to range from $1.28  to $1.96 per share.
Revenue rose 24.1% to $119.22 million from a year ago; analysts expected $121.06 million. 
Krystal Biotech Inc's reported EPS for the quarter was $1.79​.
The company reported quarterly net income of $54.77 million.
Krystal Biotech Inc shares had fallen by 8.2% this quarter and gained 38.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 7.6% in the last three months.​ 
In the last 30 days, four analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." 
Wall Street's median 12-month price target for Krystal Biotech Inc is $386.50, about 11.7% above its last closing price of $341.12
This summary was machine generated from LSEG data August 3 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
1.66
1.79
Beat
Mar. 31 2026 
1.42
1.83
Beat
Dec. 31 2025 
1.41
1.70
Beat
Sep. 30 2025 
1.09
2.66
Beat